About this trial
Benign prostatic hyperplasia (BPH) is a common condition affecting aging men, often leading to lower urinary tract symptoms (LUTS). While Minimally Invasive Surgical Therapies (MIST) procedures offer less invasive alternatives to traditional surgery, some patients experience symptom recurrence or require further intervention due to lack of adequate relief of obstruction. Treatment of persistent obstruction after MIST therapy (BPH salvage therapy) typically requires surgical intervention like transurethral resection of prostate (TURP). This study proposes to evaluate the effectiveness of in-office transperineal laser ablation (TPLA) using the Echolaser system as a minimally invasive treatment option for these patients, potentially avoiding more invasive surgical procedures. The Cleveland Clinic sees a high volume of BPH salvage patients, making this an ideal setting for this research.
Eligibility criteria
Qualifiers
Men > 40 years old
History of Minimally invasive BPH procedure within the last 5 years.
IPSS >= 12
Prostate Volume 30 - 80 gr as assessed by CT, MRI or TRUS.
Disqualifiers
Indwelling catheter or intermittent catheterization
History of urethral strictures
Previous diagnosis of Prostate cancer
Active UTI or prostatitis
Trial design
Treatments tested in this trial
- Transperineal Laser Ablation (TPLA)
Treatment groups
Sponsors and collaborators
The Cleveland Clinic
Lead sponsor
Rocamed Inc
Collaborator